# Prevention of Periprosthetic Bone Loss After Total Hip Replacement by Annual Bisphosphonate Therapy

> **NCT02838121** · PHASE3 · COMPLETED · sponsor: **Mel Shiuann-Sheng Lee** · enrollment: 62 (actual)

## Conditions studied

- Prevention of BMD Loss After THR
- Serum Markers of Bone Turnover
- Functional Outcomes

## Interventions

- **DRUG:** Aclasta
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02838121
- **Lead sponsor:** Mel Shiuann-Sheng Lee
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2013-01
- **Final completion:** 2016-06
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2016-07-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02838121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02838121, "Prevention of Periprosthetic Bone Loss After Total Hip Replacement by Annual Bisphosphonate Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02838121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*